Trade IBRX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
ImmunityBio, Inc. (IBRX) is trading at US$7.97, down 5.18% today as of Aug 28, 12:34 EDT. The company has a market capitalisation of US$8.26B. Over the past 52 weeks, IBRX has traded between US$1.95 and US$12.43. On Syfe you can trade IBRX with $0 commission and add it to your watchlist.
| Previous close | US$8.40 |
|---|---|
| Market cap | US$8.26B |
| 52-week range | US$1.95 – US$12.43 |
| Volume | 12.14M |
| Exchange | US |
Add to Watchlist
Set Price Alert
ImmunityBio, Inc.
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Year: 2021
ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing
Jul 7, 7:49 AM · MT Newswires
ImmunityBio, Inc. (IBRX) stock is trading at US$7.97, -5.18% from the previous close of US$8.40.
The market cap for ImmunityBio, Inc. (IBRX) stock is approximately US$8.26B.
The 52-week high for ImmunityBio, Inc. (IBRX) stock is US$12.43.
The 52-week low for ImmunityBio, Inc. (IBRX) stock is US$1.95.
ImmunityBio, Inc. (IBRX) does not currently pay a dividend.
Stay on top of IBRX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
